CHF306.70
6.79% yesterday
SIX Swiss Exchange, Nov 18, 05:30 pm CET
Why the stock moved Why the stock moved Beta
ISIN
CH0012032048
Symbol
ROG
Index

Roche Stock price

CHF306.70
+25.60 9.11% 1M
+46.70 17.96% 6M
+51.20 20.04% YTD
+53.20 20.99% 1Y
-1.30 0.42% 3Y
-1.90 0.62% 5Y
+34.30 12.59% 10Y
+114.30 59.41% 20Y
SIX Swiss Exchange, Closing price Tue, Nov 18 2025
+19.50 6.79%
ISIN
CH0012032048
Symbol
ROG
Index
Industry

New AI Insights on Roche Insights AI Insights on Roche

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
CHF230.1b
Enterprise Value
CHF251.1b
Net debt
CHF21.0b
Cash
CHF12.0b
Shares outstanding
796.0m
Valuation (TTM | estimate)
P/E
26.1 | 14.5
P/S
3.7 | 3.6
EV/Sales
4.1 | 4.0
EV/FCF
19.0
P/B
8.0
Dividends
DPS
CHF9.70
Yield 1Y | 5Y
3.4% | 3.1%
Growth 1Y | 5Y
1.0% | 1.5%
Payout 1Y | 3Y
94.0% | 72.0%
Increased
25 Years
Financials (TTM | estimate)
Revenue
CHF61.6b | CHF62.9b
EBITDA
CHF21.1b | CHF25.1b
EBIT
CHF20.8b | CHF21.5b
Net Income
CHF9.4b | CHF15.8b
Free Cash Flow
CHF13.2b
Growth (TTM | estimate)
Revenue
4.8% | 4.0%
EBITDA
9.7% | 22.8%
EBIT
10.0% | 7.2%
Net Income
-11.2% | 90.9%
Free Cash Flow
16.4%
Margin (TTM | estimate)
Gross
73.9%
EBITDA
34.3% | 39.9%
EBIT
33.8%
Net
15.3% | 25.1%
Free Cash Flow
21.4%
Financial Health
Equity Ratio
31.2%
Return on Equity
26.1%
ROCE
31.0%
ROIC
-
Debt/Equity
1.2
More
EPS
CHF11.8
FCF per Share
CHF16.6
Short interest
-
Employees
103k
Rev per Employee
CHF590.0k
Show more

Create a Free Account to create an Roche alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Roche forecast:

15x Buy
56%
6x Hold
22%
6x Sell
22%

Analyst Opinions

27 Analysts have issued a Roche forecast:

Buy
56%
Hold
22%
Sell
22%

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
61,591 61,591
5% 5%
100%
- Direct Costs 16,060 16,060
4% 4%
26%
45,531 45,531
5% 5%
74%
- Selling and Administrative Expenses 13,890 13,890
4% 4%
23%
- Research and Development Expense - -
-
-
21,140 21,140
10% 10%
34%
- Depreciation and Amortization 329 329
6% 6%
1%
EBIT (Operating Income) EBIT 20,811 20,811
10% 10%
34%
Net Profit 9,429 9,429
11% 11%
15%

In millions CHF.

Don't miss a Thing! We will send you all news about Roche directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roche Stock News

Positive
Market Watch
about 8 hours ago
Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.
Positive
WSJ
about 18 hours ago
The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, when most patients are diagnosed.
Positive
Reuters
about 19 hours ago
Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer after surgery, boosting the company's shares and underpinning its traditional credentials in oncology.
More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Thomas Schinecker
Employees 103,249
Founded 1896
Website www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today